Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD<sup>+</sup> Bioavailability and Inhibition of Poly-ADP-Ribose Glycohydrolase
Glioblastoma multiforme (GBM) is an incurable brain cancer with an average survival of approximately 15 months. Temozolomide (TMZ) is a DNA alkylating agent for the treatment of GBM. However, at least 50% of the patients treated with TMZ show poor response, primarily due to elevated expression of th...
Main Authors: | Jianfeng Li, Christopher A. Koczor, Kate M. Saville, Faisal Hayat, Alison Beiser, Steven McClellan, Marie E. Migaud, Robert W. Sobol |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/15/3572 |
Similar Items
-
Regulation of Glucose Metabolism by NAD<sup>+</sup> and ADP-Ribosylation
by: Ann-Katrin Hopp, et al.
Published: (2019-08-01) -
Enzymology of Ca<sup>2+</sup>-Mobilizing Second Messengers Derived from NAD: From NAD Glycohydrolases to (Dual) NADPH Oxidases
by: Andreas H. Guse
Published: (2023-02-01) -
NAD<sup>+</sup> Homeostasis and NAD<sup>+</sup>-Consuming Enzymes: Implications for Vascular Health
by: Roberto Campagna, et al.
Published: (2023-02-01) -
Inhibition of Poly (ADP-Ribose) Glycohydrolase Accelerates Osteoblast Differentiation in Preosteoblastic MC3T3-E1 Cells
by: Yuka Sasaki, et al.
Published: (2022-05-01) -
Using TLC-MALDI-TOF to Interrogate In Vitro Peptidyl Proximal Preferences of PARP14 and Glycohydrolase Specificity
by: Zeeshan Javed, et al.
Published: (2023-08-01)